| Completed | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritone NCT02122185 | University of Chicago | Phase 2 |
| Completed | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer NCT02275039 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian NCT01927393 | City of Hope Medical Center | N/A |
| Withdrawn | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or NCT01982487 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection NCT01249443 | AIDS Malignancy Consortium | Phase 1 |
| Completed | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or R NCT02046421 | University of Chicago | Phase 1 |
| Terminated | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal C NCT01962948 | Fox Chase Cancer Center | Phase 1 / Phase 2 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT01747798 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Pri NCT01536054 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Completed | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer NCT01652794 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer NCT01494012 | Stanford University | Phase 1 |
| Completed | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer NCT01281514 | Fox Chase Cancer Center | Phase 1 |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer NCT01764789 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did No NCT01200797 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) NCT01126346 | Wake Forest University Health Sciences | N/A |
| Completed | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallop NCT00993616 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignan NCT01079832 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recur NCT01673217 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or NCT00093496 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary NCT00429793 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors NCT00408655 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal NCT00388037 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary P NCT00436501 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissu NCT00390234 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery NCT00348699 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ova NCT00466960 | University of Washington | Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallop NCT00334893 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, NCT00278343 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Witho NCT00335998 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Oxaliplatin and Topotecan in Advance Ovarian Cancer NCT00313612 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer NCT00182767 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity C NCT00132067 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer NCT00275028 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or NCT00081276 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer NCT00113373 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube NCT00126542 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carc NCT00357448 | University of Washington | Phase 1 |
| Completed | Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer NCT00096395 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer NCT00091195 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal NCT00083122 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelia NCT00538031 | City of Hope Medical Center | Phase 2 |
| Completed | Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Tre NCT00228358 | University of Washington | Phase 1 |
| Completed | Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer NCT00053365 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, o NCT00041080 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded t NCT00025155 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal C NCT00041041 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal NCT00022659 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Can NCT00036751 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leuke NCT00039091 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal C NCT00023712 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors NCT00028535 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer NCT00026091 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer NCT00016289 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallop NCT00006942 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer NCT00004032 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tu NCT02050009 | Fox Chase Cancer Center | Phase 1 |